186 related articles for article (PubMed ID: 21935898)
1. High-throughput screening of viral entry inhibitors using pseudotyped virus.
Basu A; Mills DM; Bowlin TL
Curr Protoc Pharmacol; 2010 Dec; Chapter 13():Unit 13B.3. PubMed ID: 21935898
[TBL] [Abstract][Full Text] [Related]
2. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library.
Beck S; Henß L; Weidner T; Herrmann J; Müller R; Chao YK; Grimm C; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Aug; 132():85-91. PubMed ID: 27241689
[TBL] [Abstract][Full Text] [Related]
3. Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells.
Klintworth A; Nolden T; Westhaus S; Rohrmann K; David S; Manns MP; Finke S; Ciesek S; von Hahn T
Antiviral Res; 2015 Dec; 124():122-31. PubMed ID: 26542648
[TBL] [Abstract][Full Text] [Related]
4. Pseudotyped Viruses for Marburgvirus and Ebolavirus.
Zhang L; Liu S; Wang Y
Adv Exp Med Biol; 2023; 1407():105-132. PubMed ID: 36920694
[TBL] [Abstract][Full Text] [Related]
5. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.
Khetawat D; Broder CC
Virol J; 2010 Nov; 7():312. PubMed ID: 21073718
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein.
Xiao JH; Rijal P; Schimanski L; Tharkeshwar AK; Wright E; Annaert W; Townsend A
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212933
[TBL] [Abstract][Full Text] [Related]
7. Novel Small Molecule Entry Inhibitors of Ebola Virus.
Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
[TBL] [Abstract][Full Text] [Related]
8. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
9. Retrovirus-Based Surrogate Systems for BSL-2 High-Throughput Screening of Antivirals Targeting BSL-3/4 Hemorrhagic Fever-Causing Viruses.
Radoshitzky SR; Soloveva V; Gharaibeh D; Kuhn JH; Bavari S
Methods Mol Biol; 2018; 1604():393-403. PubMed ID: 28986850
[TBL] [Abstract][Full Text] [Related]
10. A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with Traditional Chinese Medicines.
Yang Y; Cheng H; Yan H; Wang PZ; Rong R; Zhang YY; Zhang CB; Du RK; Rong LJ
J Med Virol; 2017 May; 89(5):908-916. PubMed ID: 27704591
[TBL] [Abstract][Full Text] [Related]
11. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
12. Ebola virus uses clathrin-mediated endocytosis as an entry pathway.
Bhattacharyya S; Warfield KL; Ruthel G; Bavari S; Aman MJ; Hope TJ
Virology; 2010 May; 401(1):18-28. PubMed ID: 20202662
[TBL] [Abstract][Full Text] [Related]
13. Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site.
Wang LL; Palermo N; Estrada L; Thompson C; Patten JJ; Anantpadma M; Davey RA; Xiang SH
Antiviral Res; 2021 May; 189():105059. PubMed ID: 33705865
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
[TBL] [Abstract][Full Text] [Related]
15. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
[TBL] [Abstract][Full Text] [Related]
16. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.
Whitt MA
J Virol Methods; 2010 Nov; 169(2):365-74. PubMed ID: 20709108
[TBL] [Abstract][Full Text] [Related]
17. Ebola Virus Entry: From Molecular Characterization to Drug Discovery.
Salata C; Calistri A; Alvisi G; Celestino M; Parolin C; Palù G
Viruses; 2019 Mar; 11(3):. PubMed ID: 30893774
[TBL] [Abstract][Full Text] [Related]
18. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
[No Abstract] [Full Text] [Related]
19. A Novel Class of Small Molecule Compounds that Inhibit Hepatitis C Virus Infection by Targeting the Prohibitin-CRaf Pathway.
Liu S; Wang W; Brown LE; Qiu C; Lajkiewicz N; Zhao T; Zhou J; Porco JA; Wang TT
EBioMedicine; 2015 Nov; 2(11):1600-6. PubMed ID: 26870784
[TBL] [Abstract][Full Text] [Related]
20. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.
Cui Q; Du R; Anantpadma M; Schafer A; Hou L; Tian J; Davey RA; Cheng H; Rong L
Viruses; 2018 Mar; 10(4):. PubMed ID: 29584652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
